Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

iniparib (BSI 201)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Sanofi

Drug class:

PARP1 inhibitor

Related drugs:

BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Peritoneal Cancer	BRCA2 mutation	Peritoneal Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Fallopian Tube Cancer	BRCA2 mutation	Fallopian Tube Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	BSI 201 Sensitive: C4 – Case Studies BSI 201 Sensitive : C4	BSI 201 Sensitive: C4 – Case Studies BSI 201 Sensitive : C4